Skip to main content
. 2019 Oct 10;134(5):899–908. doi: 10.1097/AOG.0000000000003500

Fig. 3. Forest plot of supportive secondary efficacy endpoints in the phase 3 studies (modified intent-to-treat population). Q, question; FSEP-R, Female Sexual Encounter Profile–Revised; BMT, bremelanotide; FSDS-DAO, Female Sexual Distress Scale–Desire/Arousal/Orgasm; FSFI, Female Sexual Function Index; PBO, placebo.

Fig. 3.

Kingsberg. Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol 2019.